http://ir.arrowheadpharma.com/news-releases/news-release-details/...

http://ir.arrowheadpharma.com/news-...harmaceuticals-presents-arc-520-clinical-data

Key results include the following:

• One HBeAg-negative patient serocleared HBsAg post ARC-520
• Mild ALT changes off ARC-520 therapy coincided with sustained host responses in 2/3 HBeAg-positive and 2/5 HBeAg-negative patients
• A single dose of ARC-520 in combination with ETV reduced HBsAg for up to 44 weeks
• Multiple doses of ARC-520 resulted in additional HBsAg reductions in all patients by as much 5.3 Log10
• ARC-520 in combination with ETV was effective at rapidly suppressing HBV DNA